home / stock / cingw / cingw quote
Last: | $0.01 |
---|---|
Change Percent: | 0.0% |
Open: | $0.01 |
Close: | $0.01 |
High: | $0.010001 |
Low: | $0.0099 |
Volume: | 17,586 |
Last Trade Date Time: | 07/16/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.01 | $0.01 | $0.01 | $0.010001 | $0.0099 | 17,586 | 07-16-2024 |
$0.0099 | $0.0099 | $0.0099 | $0.01 | $0.0098 | 5,960 | 07-15-2024 |
$0.0099 | $0.0099 | $0.0099 | $0.0099 | $0.0099 | 500 | 07-12-2024 |
$0.0109 | $0.0109 | $0.0109 | $0.0109 | $0.0109 | 252 | 07-11-2024 |
$0.0075 | $0.0081 | $0.0075 | $0.008601 | $0.0075 | 6,919 | 07-10-2024 |
$0.0077 | $0.0149 | $0.0077 | $0.015 | $0.0076 | 10,260 | 07-09-2024 |
$0.0075 | $0.008 | $0.0075 | $0.008 | $0.0075 | 8,909 | 07-08-2024 |
$0.0074 | $0.0178 | $0.0074 | $0.0183 | $0.0074 | 18,568 | 07-04-2024 |
$0.0074 | $0.0178 | $0.0074 | $0.0183 | $0.0074 | 18,568 | 07-03-2024 |
$0.0108 | $0.0103 | $0.0108 | $0.0108 | $0.0072 | 36,706 | 06-28-2024 |
$0.01395 | $0.01395 | $0.01395 | $0.01395 | $0.01395 | 1,198 | 06-25-2024 |
$0.0179 | $0.0179 | $0.0179 | $0.0179 | $0.0179 | 500 | 06-24-2024 |
$0.0102 | $0.011 | $0.0102 | $0.0111 | $0.01 | 6,830 | 06-21-2024 |
$0.0103 | $0 | $0.0103 | $0 | $0 | 50 | 06-20-2024 |
$0.0103 | $0.0102 | $0.0103 | $0.0103 | $0.0102 | 1,996 | 06-17-2024 |
$0.0182 | $0.0199 | $0.0182 | $0.0199 | $0.0182 | 681 | 06-13-2024 |
$0.0199 | $0.02 | $0.0199 | $0.02 | $0.0199 | 18,803 | 06-12-2024 |
$0.01 | $0.0124 | $0.01 | $0.0124 | $0.01 | 39,869 | 06-11-2024 |
$0.02 | $0.02 | $0.02 | $0.02 | $0.02 | 500 | 06-10-2024 |
$0.02 | $0.0199 | $0.02 | $0.02 | $0.0199 | 1,000 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Cingulate Inc. Warrants Company Name:
CINGW Stock Symbol:
NASDAQ Market:
Cingulate Inc. Warrants Website:
KANSAS CITY, Kan., June 28, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (the “Company”) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generatio...
Twelve Required Registration Batches Completed New Drug Application Being Prepped for Submission KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- In alignment with U.S. Food and Drug Administration (FDA) requirements, Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company util...
Phase 3 Data Collected to Date Sufficient for Submission of New Drug Application CTx-1301 Could Benefit >60% of ADHD Patients Currently Using Immediate-Release Booster Doses Advancing Discussions with Commercialization Partners Ready to Engage with Payers for Reimbursem...